Ann: Updated guidance for PAT-DX1 phase 1 clinical study, page-6

@mattyedw did the good Dr mention anything about this in his recent emails in which you said he was discussing "transformative" events being imminent? "Sporadic issues" with the cell lines used to produce our product is going to be a real bad look for any bigger partners sniffing the water.

What "sporadic" issue this time, what other sporadic issue could it be next time? How can they confidently say there won't be any more, or that they can resolve the ones that do? They need their GMP batch to be absolute. IMO this won't just delay the Phase 1 trial commencing but any potential deals that may have been in the works, for both products. Potential partners are going to be asking the above in much more detail and want rigorous analysis done by Patrys' team to know whether or not they can get these issues sorted for good before any deals are signed.

For anyone not familiar with biotechs, this is not abnormal, shit happens and it's a tough stretch getting things from the bench to the clinic. But all the more reason you need to understand that the things people post and claim on here are their own opinions and unless you see an announcement from the company itself with a related statement or update, all of these posts are exactly that, opinions.

"10c by Christmas 2022", "rerates imminent", "deals imminent". Yes this delay was unfortunate and unforeseen, but that's exactly why no weight should be tied to those posts on here telling you things are about to kick off and you'll miss the boat if you don't get on now.

DYOR.